Michael P. Stansky net worth and biography

Michael Stansky Biography and Net Worth

Director of TriSalus Life Sciences

Mr. Stansky was a Managing Director of Tudor Investment Corporation where he was responsible for long/short equity, crossover, and venture capital investments. He helped establish Tudor’s equity investment group in 1994 and retired from active investment management in 2008. From 1985 to 1994, Mr. Stansky was an analyst and portfolio manager at Wellington Management Company. He currently serves on the boards of Insightec and Momentis Surgical. Past board directorships include MAKO Surgical Corp., OrthoSensor and TransMedics, Inc. He has Certified Public Accountant and Chartered Financial Analyst designations. Mr. Stansky holds a B.A. in Accounting from the University of Massachusetts and a M.B.A. from Harvard Business School.

What is Michael P. Stansky's net worth?: The estimated net worth of Michael P. Stansky is at least $5.21 million as of May 15th, 2026. Stansky owns 1,240,722 shares of TriSalus Life Sciences stock worth more than $5,211,032 as of June 22nd. This net worth evaluation does not reflect any other assets that Stansky may own. Learn More about Michael P. Stansky's net worth.
How do I contact Michael P. Stansky?: The corporate mailing address for Stansky and other TriSalus Life Sciences executives is 6272 West 91st Avenue, Westminster, CO 80031, United States. TriSalus Life Sciences can also be reached via phone at 888-321-5212 and via email at [email protected]. Learn More on Michael P. Stansky's contact information.
Has Michael P. Stansky been buying or selling shares of TriSalus Life Sciences?: In the last ninety days, Michael P. Stansky has bought $1,525,000.00 in TriSalus Life Sciences stock. Most recently, on Friday, May 15th, Michael P. Stansky bought 200,000 shares of TriSalus Life Sciences stock. The stock was acquired at an average cost of $2.50 per share, with a total value of $500,000.00. Following the completion of the transaction, the director now directly owns 399,698 shares of the company's stock, valued at $999,245. Learn More on Michael P. Stansky's trading history.
Who are TriSalus Life Sciences' active insiders?: TriSalus Life Sciences' insider roster includes Bryan Cox (Chief of Research), Gary Gordon (Director), Richard Marshak (Insider), George Martin (Director), Michael Stansky (Director), Mary Szela (Chief Executive Officer, President and Director), and Mats Wahlstrom (Director). Learn More on TriSalus Life Sciences' active insiders.
Are insiders buying or selling shares of TriSalus Life Sciences?: During the last twelve months, TriSalus Life Sciences insiders bought shares 5 times. They purchased a total of 719,682 shares worth more than $1,804,176.38. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 30,150 shares worth more than $119,849.35. The most recent insider tranaction occured on May, 15th when Director Mats Wahlstrom bought 60,000 shares worth more than $151,800.00. Insiders at TriSalus Life Sciences own 16.3% of the company. Learn More about insider trades at TriSalus Life Sciences.
Information on this page was last updated on 5/15/2026.

Michael P. Stansky Insider Trading History at TriSalus Life Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/15/2026	Buy	410,000	$2.50	$1,025,000.00	1,240,722
5/15/2026	Buy	200,000	$2.50	$500,000.00	399,698

Michael P. Stansky Buying and Selling Activity at TriSalus Life Sciences

TriSalus Life Sciences Company Overview

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Today's Range

Now: $4.20

$3.95

$4.23

50 Day Range

MA: $3.87

$2.52

$4.65

2 Week Range

Now: $4.20

$2.20

$7.95

Volume

229,068 shs

Average Volume

296,130 shs

Market Capitalization

$257.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49